Lupin launches antidepressant drug

Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Lupin’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic equivalent of Eli Lilly and Company’s  Prozac® Tablets, 10 mg and 20 mg. It is indicated in the treatment of:

• Major Depressive Disorder (MDD)

Fluoxetine is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to 18 years

• Obsessive Compulsive Disorder (OCD)

Fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD)

• Bulimia Nervosa

Fluoxetine is indicated for the acute and maintenance treatment of binge‑eating and vomiting behaviors in adult patients with moderate to severe Bulimia Nervosa.

• Panic Disorder

Fluoxetine is indicated for the acute treatment of Panic Disorder, with or without agoraphobia, in adult patients.

Fluoxetine Tablets USP, 10 mg and 20 mg (RLD: Prozac®) had an annual sales of approximately USD 53 million in the US (IQVIA MAT June 2019).

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.